223 related articles for article (PubMed ID: 37076096)
21. Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
Dave RG; Geevar T; Mammen JJ; Vijayan R; Mahasampath G; Nair SC
Indian J Pathol Microbiol; 2021; 64(1):117-122. PubMed ID: 33433420
[TBL] [Abstract][Full Text] [Related]
22. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab.
Yamaguchi T; Shinozawa K; Nagatoishi S; Mitsuhashi A; Bingo M; Inaba H; Amano K; Tsumoto K; Kinai E
Thromb Res; 2023 Feb; 222():131-139. PubMed ID: 36657269
[TBL] [Abstract][Full Text] [Related]
23. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.
Teranishi-Ikawa Y; Soeda T; Koga H; Yamaguchi K; Kato K; Esaki K; Asanuma K; Funaki M; Ichiki M; Ikuta Y; Ito S; Joyashiki E; Komatsu SI; Muto A; Nishimura K; Okuda M; Sanada H; Sato M; Shibahara N; Wakabayashi T; Yamaguchi K; Matsusaki A; Sampei Z; Shiraiwa H; Konishi H; Kawabe Y; Hattori K; Kitazawa T; Igawa T
J Thromb Haemost; 2024 Feb; 22(2):430-440. PubMed ID: 37940048
[TBL] [Abstract][Full Text] [Related]
24. Emicizumab for the treatment of acquired hemophilia A.
Knoebl P; Thaler J; Jilma P; Quehenberger P; Gleixner K; Sperr WR
Blood; 2021 Jan; 137(3):410-419. PubMed ID: 32766881
[TBL] [Abstract][Full Text] [Related]
25. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.
Kaneda M; Kawasaki R; Matsumoto N; Abe H; Tashiro Y; Inokuchi Y; Yasuno H; Sasaki-Noguchi M; Soeda T; Yoshimura Y; Oka T
J Thromb Haemost; 2021 Dec; 19(12):2938-2946. PubMed ID: 34418287
[TBL] [Abstract][Full Text] [Related]
26. Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial.
Takeyama M; Ozu N; Kasama S; Kasahara M; Matsumoto M; Shima M; Nogami K
BMJ Open; 2023 Jul; 13(7):e072565. PubMed ID: 37429679
[TBL] [Abstract][Full Text] [Related]
27. Hemophilia A: Emicizumab monitoring and impact on coagulation testing.
Nardi MA
Adv Clin Chem; 2023; 113():273-315. PubMed ID: 36858648
[TBL] [Abstract][Full Text] [Related]
28. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
Nogami K
Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
[TBL] [Abstract][Full Text] [Related]
29. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
[TBL] [Abstract][Full Text] [Related]
30. Clot Waveform Analysis for Hemostatic Abnormalities.
Wada H; Shiraki K; Matsumoto T; Shimpo H; Shimaoka M
Ann Lab Med; 2023 Nov; 43(6):531-538. PubMed ID: 37387486
[TBL] [Abstract][Full Text] [Related]
31. Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma.
Tripodi A; Chantarangkul V; Novembrino C; Scalambrino E; Boscolo-Anzoletti M; Clerici M; Rossi F; Peyvandi F
Clin Chem Lab Med; 2020 Sep; 59(2):365-371. PubMed ID: 32892172
[TBL] [Abstract][Full Text] [Related]
32. Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy.
Hatayama Y; Motokura T; Hosoda Y; Suzuki S; Namba H; Kato K; Kojima N; Horie T; Iwamoto T; Yamashita N; Ichikawa H; Fukuda T
Clin Appl Thromb Hemost; 2022; 28():10760296221082992. PubMed ID: 35225012
[TBL] [Abstract][Full Text] [Related]
33. [Update on factor (F) VIII structure and function-related hemostatic coagulation and its regulatory mechanism (s)].
Nogami K
Rinsho Ketsueki; 2021; 62(7):781-789. PubMed ID: 34349063
[TBL] [Abstract][Full Text] [Related]
34. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
[TBL] [Abstract][Full Text] [Related]
35. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
[TBL] [Abstract][Full Text] [Related]
36. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
[TBL] [Abstract][Full Text] [Related]
37. Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis.
Haku J; Nogami K; Matsumoto T; Ogiwara K; Shima M
J Thromb Haemost; 2014; 12(3):355-62. PubMed ID: 24354697
[TBL] [Abstract][Full Text] [Related]
38. The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?
Bowyer AE; Maclean RM; Kitchen S
Int J Lab Hematol; 2023 Jun; 45(3):368-376. PubMed ID: 36710421
[TBL] [Abstract][Full Text] [Related]
39. Functional determination of emicizumab in presence of factor VIII activity.
Hamedani NS; Donners AAMT; van Luin M; Gasper S; Rühl H; Klein C; Albert T; El Amrani M; Pötzsch B; Oldenburg J; Müller J
J Thromb Haemost; 2023 Dec; 21(12):3490-3500. PubMed ID: 37741510
[TBL] [Abstract][Full Text] [Related]
40. Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A.
Takeyama M; Matsumoto N; Abe H; Harada S; Ogiwara K; Furukawa S; Shimonishi N; Nakajima Y; Yada K; Soeda T; Nogami K
Pediatr Blood Cancer; 2023 Oct; 70(10):e30590. PubMed ID: 37467119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
